Sebela Pharmaceuticals, through its Braintree Laboratories subsidiary, has reported detailed positive Phase 3 results showing that investigational tegoprazan significantly increased heartburn-free days in adults with non-erosive reflux disease (NERD). The 783-patient TRIUMpH-NERD trial, highlighted at the American College of Gastroenterology’s 2026 Annual Scientific Meeting on October 11, demonstrated mean 24-hour heartburn-free days of 26.2% with tegoprazan 50 mg and 30.1% with tegoprazan 100 mg, compared with 17.3% for placebo during the four-week randomized treatment period.
The findings provide additional detail beyond the positive topline results initially announced in April 2025, including nighttime heartburn outcomes, regurgitation analyses and symptom patterns during a subsequent 20-week extension. Both studied doses met the primary efficacy endpoint, while the company’s latest presentation also described improvements in days without regurgitation and days free of both principal reflux symptoms. However, the regurgitation measures were exploratory, and the extension was open-label, creating important distinctions between the strength of the different findings.
Tegoprazan is already marketed as K-CAB in several countries, including South Korea, but it remains investigational in the United States. Braintree Laboratories submitted a New Drug Application to the United States Food and Drug Administration on January 9, 2026, seeking authorisation for heartburn associated with NERD, healing of erosive esophagitis and maintenance of erosive esophagitis healing in adults. Sebela Pharmaceuticals anticipates a United States regulatory decision in January 2027, although approval remains subject to the agency’s evaluation.
The clinical opportunity is substantial because acid-suppressing medicines are already widely used, yet incomplete symptom relief remains a problem for some patients with gastroesophageal reflux disease. Tegoprazan belongs to the potassium-competitive acid blocker class, which offers a different mechanism of proton pump inhibition from conventional proton pump inhibitors. Its commercial prospects will depend not simply on statistically significant symptom improvements, but on the magnitude of benefit, safety, differentiation from existing treatments and eventual reimbursement conditions.
What do the TRIUMpH-NERD Phase 3 results reveal about tegoprazan’s heartburn efficacy?
The TRIUMpH-NERD study was a multicentre, randomized, double-blind, placebo-controlled Phase 3 trial involving 783 adults with symptomatic non-erosive reflux disease. Participants received once-daily tegoprazan 50 mg, tegoprazan 100 mg or placebo for four weeks, followed by a 20-week extension period. The primary endpoint measured the percentage of 24-hour heartburn-free days through Week 4, providing a patient-reported assessment of symptom control throughout the day rather than measuring gastric acidity alone.
Sebela Pharmaceuticals reported least-squares mean heartburn-free days of 17.3% with placebo, 26.2% with tegoprazan 50 mg and 30.1% with tegoprazan 100 mg. The treatment differences were statistically significant, with a p-value of 0.0006 for the lower dose and below 0.0001 for the higher dose. These results translate into absolute improvements of 8.9 and 12.8 percentage points over placebo, respectively, alongside the company’s reported relative increases of 51% and 74%.
The distinction between absolute and relative improvement is important when interpreting the clinical results. A 74% relative increase in heartburn-free days does not mean that 74% of patients became symptom-free or that the treatment eliminated symptoms for three-quarters of the study period. The 30.1% figure describes the adjusted mean proportion of days without heartburn across the four-week assessment, meaning symptoms remained present on a substantial proportion of days despite treatment.
The company also reported that heartburn-free days increased during the randomized treatment period. On Day 28, the reported proportions were 38.9% for tegoprazan 50 mg, 45.6% for tegoprazan 100 mg and 26.7% for placebo. These time-specific findings suggest improvement during treatment, although they measure a different assessment window from the primary endpoint averaged across four weeks.
Both doses demonstrated efficacy against placebo, but the disclosed results do not establish that the 100 mg dose is statistically superior to the 50 mg dose. That conclusion would require an appropriate direct comparison, supported by the trial’s statistical analysis. Regulatory evaluation will also consider whether any additional benefit from the higher dose is justified by its safety and exposure profile.
Why do nighttime heartburn and regurgitation outcomes matter for patients with non-erosive reflux disease?
Nighttime heartburn is an important clinical consideration because reflux symptoms can interfere with sleep and contribute to persistent discomfort even when daytime treatment appears adequate. The TRIUMpH-NERD trial included the percentage of days without nighttime heartburn as a key secondary endpoint. Sebela reported adjusted mean values of 27.0% for placebo, 36.1% for tegoprazan 50 mg and 39.9% for tegoprazan 100 mg.
Both tegoprazan doses demonstrated statistically significant improvements against placebo, with p-values of 0.0017 and below 0.0001, respectively. The corresponding absolute differences were 9.1 and 12.9 percentage points. These findings extend the primary efficacy result by showing that treatment benefits were observed during nighttime assessments, although the company did not establish that the improvements directly translated into better sleep quality or daytime functioning.
Regurgitation represents a different therapeutic challenge because suppressing gastric acid does not necessarily prevent stomach contents from moving into the esophagus. Patients may continue experiencing regurgitation even when the refluxed material becomes less acidic, meaning acid control and the physical occurrence of reflux are not interchangeable outcomes. The Lyon Consensus 2.0 framework recognises this distinction when evaluating persistent reflux symptoms and their underlying mechanisms.
Sebela reported that both tegoprazan doses increased the percentage of days without regurgitation and the percentage of days free of both heartburn and regurgitation. For the combined symptom-free endpoint, relative improvements over placebo were 60% with tegoprazan 50 mg and 76% with tegoprazan 100 mg. Treatment differences were reported from Day 1, supporting the possibility of early symptomatic benefit.
However, regurgitation was a prespecified exploratory endpoint rather than the trial’s primary outcome. The announcement did not provide complete absolute event-free percentages, confidence intervals or detailed statistical testing information for these exploratory analyses. Consequently, the findings support further assessment of broader symptom relief but should not be presented as equivalent in evidentiary strength to the confirmed primary heartburn endpoint.
Can tegoprazan’s rapid acid suppression provide an advantage over conventional proton pump inhibitors?
Tegoprazan belongs to the potassium-competitive acid blocker class, which reversibly inhibits the gastric proton pump through competition with potassium ions. Conventional proton pump inhibitors, including omeprazole, esomeprazole and lansoprazole, act through a different mechanism that involves acid-dependent activation followed by inhibition of the proton pump. These pharmacological differences can influence the onset and duration of acid suppression, although clinical benefits must be established through appropriately designed treatment comparisons.
Sebela has reported that tegoprazan increased intragastric pH above 4 within 45 minutes of administration in Phase 1 pharmacodynamic studies. This observation supports rapid acid-suppressing activity under the tested conditions, but the pharmacodynamic result should not be confused with the time required to achieve meaningful symptom relief. Changes in gastric pH and patient-reported heartburn outcomes measure different aspects of treatment performance.
The Phase 3 trial’s observation of treatment differences from Day 1 is therefore clinically relevant. Early symptom improvement may contribute to treatment satisfaction, particularly among patients experiencing frequent discomfort. However, the announcement did not provide a direct Day 1 comparison with a proton pump inhibitor, and the study cannot establish that tegoprazan relieves non-erosive reflux symptoms faster than every existing acid-suppressing medicine.
Proton pump inhibitors remain widely prescribed, supported by substantial clinical experience, generic availability and established treatment guidelines. The American College of Gastroenterology has recommended an initial proton pump inhibitor trial for appropriate patients with typical reflux symptoms and has recognised intermittent or on-demand therapy as an option for selected patients with non-erosive reflux disease. A new entrant must therefore demonstrate clinically relevant differentiation in a market where many patients already have effective and relatively inexpensive treatment options.
The TRIUMpH-NERD study provides evidence of tegoprazan’s benefit over placebo, but not superiority over proton pump inhibitors in the non-erosive population. That difference is essential when evaluating the company’s broader claims of competitive advantage. Active-comparator evidence from the separate erosive esophagitis programme contributes additional information, but the two patient populations and their endpoints are not directly interchangeable.
What do the 20-week extension results suggest about sustained control of reflux symptoms?
Following the four-week placebo-controlled treatment period, participants entered a 20-week open-label extension designed to provide additional treatment experience and information about symptom patterns over time. Sebela reported that the least-squares mean percentage of 24-hour heartburn-free days averaged 48% with tegoprazan 50 mg and 50% with tegoprazan 100 mg during this extension. Similar patterns were reported for days without regurgitation, although complete numerical results were not included in the announcement.
These observations suggest that symptom control remained measurable beyond the initial randomized period. However, interpreting the extension requires consideration of its open-label design, in which the absence of an ongoing blinded placebo comparison limits conclusions about the magnitude of the sustained treatment effect. Participants who continue into an extension may also differ from those who discontinue, potentially influencing observed outcomes.
The extension results do not demonstrate that the treatment effect increased steadily for every patient or that the improvements would persist after therapy was stopped. Additional information about patient retention, missing data, background medication use and discontinuation patterns would help clarify the reliability of the longer-duration findings. Those details are particularly relevant because gastroesophageal reflux disease often requires recurrent or sustained management.
Longer-term safety assessment is another important consideration. Potent acid suppression can have implications for gastrointestinal physiology, medication interactions and laboratory markers, including gastrin concentrations. While the company’s broader clinical programme includes longer treatment periods, the full safety database remains important to the FDA’s assessment of appropriate treatment duration and dosing.
How do the new erosive esophagitis results strengthen tegoprazan’s broader GERD development programme?
Alongside the non-erosive reflux findings, Sebela presented a separate post hoc analysis from the Phase 3 TRIUMpH-EE programme evaluating healing and maintenance of erosive esophagitis. The analysis received an American College of Gastroenterology Presidential Award and applied the Lyon Consensus 2.0 framework to classify patients according to the strength of objective evidence supporting gastroesophageal reflux disease. This created a clinically relevant distinction between patients with more definitive erosive disease and those with less conclusive endoscopic findings.
Under this framework, Los Angeles Grades B, C and D were classified as conclusive gastroesophageal reflux disease, while Grade A was considered inconclusive. The analysis drew on endoscopic assessments from the Phase 3 programme, including blinded central review of procedural recordings. Such classification is important because the extent of visible esophageal injury can influence both diagnostic certainty and the interpretation of acid-suppressing treatment outcomes.
Among patients classified as having conclusive gastroesophageal reflux disease, the reported healing rate was 75.4% with tegoprazan compared with 60.7% for lansoprazole at Week 2. Cumulative healing by Week 8 reached 83.4% and 72.7%, respectively, with statistically significant differences at both assessments. The reported superiority findings for healing involved tegoprazan 100 mg, while both 50 mg and 100 mg demonstrated statistically significant advantages over lansoprazole for maintenance of healing at Week 24 in the defined conclusive-disease population.
The findings provide a possible explanation for why disease classification may influence treatment response. Patients with objectively established erosive reflux disease could represent a population in which stronger or more consistent acid suppression produces a measurable advantage over conventional treatment. However, the latest analysis was conducted after the original trial and should not be treated as an independently randomized trial designed specifically to prospectively test the Lyon Consensus classification.
No statistically significant differences were observed between treatment groups among patients classified as having inconclusive gastroesophageal reflux disease. That finding limits any claim that tegoprazan is uniformly superior across all erosive disease categories. It also illustrates how more precise patient classification could influence future clinical research and treatment evaluation.
How reassuring is tegoprazan’s safety profile across the Phase 3 TRIUMpH programme?
Sebela described the safety and tolerability findings across its pivotal studies as broadly comparable with placebo and active treatment comparators. The company reported that individual treatment-emergent adverse events occurred at rates of approximately 3% and were generally mild and transient, while serious adverse events occurred at approximately 2% with similar rates between treatment groups. These figures should not be interpreted as establishing that only 3% of all treated patients experienced any adverse event.
The company also stated that mean serum gastrin concentrations for tegoprazan and lansoprazole remained within the reported normal range of 0 to 180 pg/mL during treatment. Gastrin monitoring is relevant because sustained suppression of gastric acidity can influence physiological feedback mechanisms involved in gastric secretion. Normal mean values provide useful context but do not exclude individual elevations or establish the absence of longer-term complications.
The detailed safety assessment will require information about adverse-event incidence by dose, treatment duration, discontinuations, laboratory findings and the characteristics of serious events. Differences between the placebo-controlled non-erosive reflux study and the active-comparator erosive esophagitis trial also matter when interpreting pooled safety observations. A favourable overall description does not remove the need to examine uncommon adverse reactions and longer-term tolerability.
Tegoprazan has already received marketing authorisation in 24 countries, according to Sebela’s October disclosure, providing international experience beyond the United States programme. Nevertheless, foreign marketing authorisations are not a substitute for FDA evaluation of the submitted application, proposed prescribing information and supporting safety database. Any United States approval would be specific to the indications, doses and conditions authorised by the agency.
Can tegoprazan compete with vonoprazan in the United States potassium-competitive acid blocker market?
The United States market already includes a commercially available potassium-competitive acid blocker, vonoprazan, marketed as Voquezna by Phathom Pharmaceuticals. Vonoprazan has FDA-approved indications covering erosive esophagitis, maintenance of healing, heartburn associated with non-erosive gastroesophageal reflux disease and specified Helicobacter pylori treatment regimens. Consequently, tegoprazan would enter an established competitive category rather than introduce the mechanism to United States prescribers for the first time.
Sebela has positioned its regurgitation findings as a potentially important differentiator, describing tegoprazan as the first potassium-competitive acid blocker to demonstrate improvement in both heartburn and regurgitation within a prospective United States Phase 3 non-erosive reflux trial. That is a company-specific characterization of the evidence and does not establish clinical superiority over vonoprazan. Direct comparisons would require studies with sufficiently similar populations, endpoints and treatment conditions, ideally involving randomized head-to-head assessment.
Vonoprazan’s approved non-erosive reflux indication is supported by placebo-controlled clinical evidence, but isolated percentages from its development programme cannot be ranked against tegoprazan’s results without accounting for differences in baseline symptom frequency and study design. Sebela reported that participants in TRIUMpH-NERD had heartburn-free days on only 6.2% of baseline days, compared with higher baseline percentages cited from other reflux treatment studies. This suggests a substantial symptom burden in the enrolled population, but it also makes unadjusted cross-trial comparisons particularly unreliable.
Beyond competing potassium-competitive acid blockers, tegoprazan would face longstanding proton pump inhibitor brands and widely available generic products. Commercial differentiation may depend on whether physicians perceive an advantage in particular symptom patterns, including nighttime heartburn or persistent regurgitation. Pricing, coverage restrictions, formulary placement and the need for prior authorisation could influence adoption even if the FDA approves the product.
Why are the FDA review and commercial partnership with HK inno.N important for Sebela Pharmaceuticals?
Tegoprazan was originally developed by South Korea’s HK inno.N Corporation, which partnered with Sebela Pharmaceuticals to support development and commercialization in the United States and Canada. Under their agreement, Braintree Laboratories is responsible for clinical development, regulatory activities, marketing and sales within the licensed territories. The partnership combines an internationally marketed molecule with a United States clinical programme designed to support local regulatory requirements.
The January 2026 New Drug Application seeks three adult indications within a single regulatory programme. These comprise relief of heartburn associated with non-erosive reflux disease, healing of erosive esophagitis and maintenance of healing after successful treatment. The combined approach could support a broad commercial proposition if the FDA authorises all requested indications, but the final scope remains subject to regulatory review.
Sebela Pharmaceuticals expects a United States regulatory decision in January 2027. That timing is a company expectation rather than confirmation that approval will occur, and the latest conference results do not represent an FDA decision. The agency must independently assess whether the submitted efficacy evidence, safety findings, manufacturing information and proposed prescribing information support the requested uses.
The company has experience commercializing gastroenterology products, but introducing another prescription acid-suppressing medicine will require additional commercial execution. The business must establish reliable distribution, secure appropriate payer access and persuade prescribers that tegoprazan provides value relative to existing alternatives. Its launch prospects will also depend on the final approved dosing and treatment duration, which cannot be assumed from the experimental regimens alone.
Sebela Pharmaceuticals is privately held, so there is no directly traded company share price through which to measure investor reaction to the October presentation. For its development partner, HK inno.N, the United States regulatory programme represents an international commercialization opportunity rather than an already realized source of United States product sales. Any future financial contribution will depend on the licensing economics, regulatory outcome and subsequent commercial performance.
What will determine whether tegoprazan’s Phase 3 success translates into routine GERD treatment?
The detailed TRIUMpH-NERD results strengthen the clinical evidence supporting tegoprazan’s ability to reduce heartburn symptoms in adults with non-erosive reflux disease. The randomized trial provides statistically significant evidence for the primary endpoint at both tested doses, supported by improvements in nighttime heartburn and exploratory findings involving regurgitation. However, the magnitude of absolute benefit, persistence of residual symptoms and absence of a proton pump inhibitor comparator in this particular study remain important considerations.
The separate erosive esophagitis analysis adds evidence supporting tegoprazan in patients with objectively established mucosal injury, particularly those classified as having conclusive gastroesophageal reflux disease under Lyon Consensus 2.0 criteria. Its results suggest that baseline disease phenotype may influence treatment differentiation. Because the analysis was post hoc, further evaluation would be valuable before using its subgroup findings to establish definitive comparative treatment conclusions.
For physicians, eventual treatment decisions will depend on whether tegoprazan offers a useful balance of symptom relief, safety, convenience and cost for specific patient populations. For payers, the presence of generic proton pump inhibitors and an approved potassium-competitive acid blocker creates a demanding environment for demonstrating incremental value. The reported advantages in nighttime symptoms and regurgitation may contribute to that assessment, but more complete evidence on patient-reported outcomes and longer-term treatment needs could improve its clinical interpretation.
The January 2027 FDA decision anticipated by Sebela Pharmaceuticals is now the principal near-term milestone. Approval across the three requested indications would give the company an opportunity to compete in both symptomatic non-erosive reflux disease and erosive esophagitis management, while a narrower authorisation or additional regulatory requirements could alter its launch strategy. The strength of the Phase 3 programme has established a substantive basis for regulatory evaluation, but the next test is whether that evidence supports an approved United States label and a commercially differentiated treatment option in an already competitive gastroenterology market.
